GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nunzia Pharmaceutical NUNZ · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2021

Net income

−$78.1m

FY2014FY2021

Free cash flow

−$86,776

FY2014FY2021

Shareholders' equity

−$94,174

FY2014FY2021

Income statement

Fiscal years

FY2021FY2020FY2019FY2018FY2017FY2015FY2014
Operating income−$78.1m−$16,327−$33,635−$27,172−$326,000−$800−$28,700
Net income−$78.1m−$9.0m−$33,635−$18,576−$326,000−$800−$28,700
Diluted earnings per share-0.18-0.04-0.00-0.88-0.00-0.04-1.40

Balance sheet

At each fiscal year end

FY2021FY2020FY2019FY2018FY2017FY2015FY2014
Total assets$5,131———$6,000——
Cash and short-term investments$131——————
Total liabilities$99,305$36,404$22,575$293,967$275,391$262,400$261,600
Debt$97,443$23,000—$23,000$23,000$182,800—
Shareholders' equity−$94,174−$36,404−$22,575−$293,967−$275,391−$262,400−$261,600
Shares outstanding434m235m235m0m434m0m0m

Cash flow

Fiscal years

FY2021FY2020FY2019FY2018FY2017FY2015FY2014
Cash from operations−$86,776−$32,294−$3,800−$3,800−$3,800——
Free cash flow−$86,776−$32,294−$3,800−$3,800−$3,800——

Latest quarters

By quarter end

Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021Jun 2021Mar 2021Dec 2020
Operating income−$227,429−$20,100−$18.7m−$78.0m−$34,527−$6,629−$15,648−$9,345
Net income−$245,403−$20,100−$18.7m−$78.0m−$34,527−$6,629−$15,648−$9.0m
Diluted earnings per share-0.00-0.00-0.04-0.18-0.00-0.00-0.00-0.04
Total assets$35,373$29,935$5,000$5,131$9,483$9,003$16,620—
Cash and short-term investments$35,373—$5,000—$483$1,503——
Debt$183,345—$132,443—————
Shareholders' equity−$191,321−$117,405−$132,304−$94,174−$88,208−$53,681−$52,052−$36,404

Valuation history

At each fiscal year end

FY2021FY2019
Price to earnings-0.0-0.3

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-97%0%-59%605%989%117%228%801008%44814%950%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 7000-to-1 reverse split · 4 Dec 2019
  • 10-to-1 reverse split · 25 Jun 2010
  • 300-to-1 reverse split · 22 Dec 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.